
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.

Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.
.webp&w=828&q=75)
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.

PolyNovo (ASX: PNV) is an advanced wound care company whose NovoSorb platform drives strong U.S.-led growth. After the March weakness from leadership changes, improving revenues and a technical breakout above the trend signal a potential bottom and renewed bullish momentum.

EBR Systems has fallen sharply after a major capital raise sparked dilution concerns. Despite the sell-off, the company continues to expand the commercialisation of its FDA-approved WiSE CRT heart-failure technology, supported by growing implant volumes, clinical studies, and international regulatory progress.

4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.